Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12605000247673
ACTRN12605000247673
Completed
Phase 4

Prevention or delay of onset of psychosis in an 'ultra high risk' group: A comparison of risperidone and placebo in combination with intensive psychological treatment

Janssen-Cilag Pharmaceuticals0 sites119 target enrollmentAugust 31, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSchizophrenia and other psychotic disordersMental Health - SchizophreniaMental Health - Other mental health disorders

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Schizophrenia and other psychotic disorders
Sponsor
Janssen-Cilag Pharmaceuticals
Enrollment
119
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 31, 2005
End Date
April 12, 2006
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Janssen-Cilag Pharmaceuticals

Eligibility Criteria

Inclusion Criteria

  • •Participants must meet 'ultra high risk' criteria as outlined in Yung, Phillips and McGorry (2004\) Treating Schizophrenia in the Prodromal Phase. London: Taylor nd Francis. Also, have not previously experienced psychotic episode, IQ \> 70, adequate English skills, and living in Melbourne metro area.

Exclusion Criteria

  • •No exclusion criteria

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Primary prevention of psychosis through interventions in the prodromal phase
ISRCTN20328848Stavanger University Hospital (Norway)240
Completed
Not Applicable
The prevention of psychosis in at risk mental state
ISRCTN21353122The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)240
Completed
Not Applicable
Prevention of psychosis with a cognitive behavioural intervention in help-seeking young people with an at risk mental state for developing psychosis
NL-OMON31359Parnassia (Den Haag)240
Recruiting
Phase 3
Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trialinvestigating the efficacy of N-Acetylcysteine (NAC) and Integrated Preventive PsychologicalIntervention (IPPI) in Subjects Clinically at High Risk for PsychosisSubjects presenting ultra-high risk (UHR) for psychosis (e.g. attenuated psychotic symptoms, brief limited intermittend psychotic symptoms or a genetic risk in combination with a decline in social functioning)
DRKS00010952Zentralinstitut für seelische Gesundheit/Central Institute of Mental Health (ZI)200
Active, not recruiting
Phase 1
Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trial investigating the efficacy of Acetylcysteine (ACC) and Integrated Preventive Psychological Intervention (IPPI) in Subjects Clinically at High Risk for Psychosis
EUCTR2014-003076-22-DECentral Institute of Mental Health Mannheim (ZI)130